News
CluePoints Opens New AsiaPac Office in Tokyo
CluePoints, the premier provider of Central Statistical Monitoring, Risk-Based Quality Management and Data Quality Oversight Software for clinical trials, announced further expansion in Japan with the opening of a new office in Tokyo. Dedicated to serving their Japanese clients,...
News
Piramal Pharma Solutions invests US$ 32 mn to expand Michigan facility
Piramal Pharma Limited’s pharma solutions business, a leading contract development and manufacturing organization (CDMO), is investing US$ 32 million to expand its facility in Michigan with additional capacity and new capabilities for the development and manufacturing of active pharmaceutical...
Drug Research
U.S. FDA confirms Pfizer COVID vaccine safe & effective
The FDA 53-page briefing document gives a green signal to Pfizer-BioNTech COVID-19 vaccine. A US roll-out of the vaccine is expected post-approval from an outside panel of scientific advisers who will review the FDA report on Thursday.
As COVID cases...
Drug Research
UK Begins The Biggest Immunization Program In Its History
The UK has begun immunizing citizens against Coronavirus.
Population above 80, the most vulnerable and the front line health care workers to be administered with the Pfizer COVID-19 vaccine in the first phase.
There is a history in the...
Drug Research
Russia Begins Sputnik V Coronavirus Vaccine Distribution
Sputnik V has been rolled out in Moscow and will be subsequently distributed across other Russian cities.
One needs to see if this will halt the growing number of COVID-19 cases in the country.
Sputnik V to be...
Drug Research
KaliVir Immunotherapeutics, Astellas ink research agreement to develop and commercialise VET2-L2 novel oncolytic virus
KaliVir Immunotherapeutics LLC and Astellas Pharma Inc announced that they entered into a worldwide licensing agreement for the research, development, and commercialization of VET2-L2, an intravenously administered oncolytic virus for Immuno-Oncology, as well as a research collaboration to generate...
News
Codex DNA Releases New Synthetic Genomes for the Fight Against COVID-19
Codex DNA, Inc. announced the release of seven new synthetic SARS-CoV-2 genomes for use in the development of vaccines, therapeutics, and diagnostics to help in the COVID-19 pandemic response. With our BioXp™ 3250 system, the world’s first and only...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read